Cardiometabolic Status in Childhood Acute Lymphoblastic Leukemia

University of Minnesota (UMN)

Status: Withdrawn

Conditions: Acute Lymphoblastic Leukemia

Study type: Observational

Funder types: Other

Identifiers

NCT01688752

2012NTLS086

Details and patient eligibility

About

This is a prospective cohort study assessing measures of cardiometabolic status, body composition, IR and GH response to stimulation after therapy in children (age 7-21 years) treated for ALL. Patients and sibling controls will be recruited from the Pediatric Hematology-Oncology Clinic at the University of Minnesota Amplatz Children's Hospital.

Full description

This is a prospective cohort study with two groups: survivors of acute lymphoblastic leukemia (ALL) who have recently completed therapy (cases) and healthy siblings (controls) frequency matched by age and sex. Subjects in each group will have two visits. For cases, the first visit will be approximately 6 months after completion of treatment for ALL; for their siblings, the first visit occur at approximately the same time. For both cases and controls, the second visit will be 2 to 2.5 years after the first visit.

Sex: All

Ages: 7 to 21 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients

  • Age 7 years to less than or equal to 21 years at time of study enrollment.
  • Acute lymphoblastic leukemia (ALL) as first cancer diagnosis and in first complete remission. Any subtype is eligible.
  • Study enrollment must take place at/after six months of completion of all chemotherapy.
  • Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, or 2. Use Karnofsky for patients > 16 years of age and Lansky for patients ≤ 16 years of age.
  • Any prior ALL therapy is allowable.

• Siblings

  • Age 7 years to less than or equal to 21 years at time of study enrollment.
  • Sibling of ALL patient.

Exclusion criteria

• Patients

  • Diagnosis of diabetes mellitus prior to ALL diagnosis or at time of study enrollment.
  • Current pregnancy
  • Prior hematopoietic cell transplant.
  • Receiving growth hormone replacement or corticosteroids at the time of enrollment.

• Siblings

  • Previously diagnosed with malignancy.
  • Diagnosis of diabetes mellitus.
  • Current pregnancy
  • Receiving growth hormone replacement or corticosteroids at the time of enrollment.

Trial design

0 participants in 2 patient groups

Sibling Controls

Description:

Healthy siblings of acute lymphoblastic leukemia (ALL) subjects frequency matched by age and sex.

Acute Lymphoblastic Leukemia Survivors

Description:

Survivors of acute lymphoblastic leukemia (ALL) who recently completed therapy.